Ultragenyx Pharmaceutical Inc., of Novato, Calif., said underwriters of the previously disclosed offering of 3 million shares of common stock have exercised in full their option to purchase an additional 450,000 shares from the company at the public offering price of $54 each, before underwriting discounts.